SPECIALTY GUIDELINE MANAGEMENT

ZORBTIVE (somatropin)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Treatment of short bowel syndrome in adult patients receiving specialized nutritional support.

All other indications are considered experimental/investigational and not medically necessary.

II. CRITERIA FOR INITIAL APPROVAL

Short bowel syndrome (SBS)1

Authorization of a total duration of 4 weeks may be granted for treatment of SBS in members who are dependent on parenteral nutrition support.

III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

IV. REFERENCES

- Zorbtive [package insert]. Rockland. MA: EMD Serono. Inc.: September 2019.
- 2. Iyer K, DiBaise JK, Rubio-Tapia A. AGA Clinical practice update on management of short bowel syndrome: Expert review. *Clin Gastroenterol Hepatol.* 2022; 20(10):2185-2194.

Zorbtive 2244-A SGM P2024.docx

pharmaceutical manufacturers that are not affiliated with CVS Caremark.

© 2024 CVS Caremark. All rights reserved.



This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of